外周T细胞淋巴瘤治疗效果及其预后影响因素分析

目的探究外周T细胞淋巴瘤(PTCL)的治疗效果,并分析其预后的相关影响因素。方法选取2000年1月—2015年12月在本院肿瘤科确诊为PTCL患者235例为观察组。选择同期在本院接受治疗的PTCL患者200例为对照组。观察组给予第1种化疗方案HyperCVAD/MA进行治疗,当患者造血功能恢复后可采用第2种化疗方案甲氨蝶呤和阿糖胞苷进行化疗;对照组给予CHOP/CHOP样方案治疗。对比两组患者的治疗效果,并根据随访结果对观察组患者预后的相关影响因素进行分析。结果观察组总有效率为77.87%(183/235),对照组总有效率为54.00%(108/200)。观察组治疗效果优于对照组(P0.05)。观察组患者中性粒细胞减少发生率高于对照组,差异有统计学意义(P0.05),而两组患者肺部感染、心脏毒性、严重贫血及血小板减少的发生率比较,差异均无统计学意义(P0.05)。不同乳酸脱氢酶水平、β_2微球蛋白水平、BEOG体能分级标准评分、骨髓侵犯、KI67指数、国际淋巴瘤预后指数积分、结外浸润部分、治疗效果及化疗疗程患者中位生存期比较,差异均有统计学意义(P0.05)。经多因素Logistic回归分析结果显示,BEOG体能分级标准评分≥2分、骨髓侵犯、国际淋巴瘤预后指数积分≥2分、结外侵犯部位1个、治疗效果及化疗疗程4个是影响预后的因素(P0.05)结论 Hyper/CVAD/MA治疗方案能有效改善患者的治疗效果,但同时也会造成中性粒细胞严重减少。影响PTCL预后的主要危险因素有BEOG体能分级标准评分、骨髓侵犯、国际淋巴瘤预后指数积分、结外侵犯部位、治疗效果及化疗疗程等,要注重改善以上因素以提升患者的预后质量。     

恶性淋巴瘤结外表现特点附248例文献综述

恶性淋巴瘤主要为霍奇金病(HD)和非霍奇金淋巴瘤(NHL)两类。HD是淋巴网状组织的恶性肿瘤,常发生于一组淋巴结而扩散至其它淋巴结和结外器官或组织,具有特征性的里-施细胞。NHL是一组异质性疾病,除侵及淋巴结外,更容易引起结外病变,临床表现复杂多样,如不仔细鉴别,往往容易引起漏诊误诊,本文综合文献收集248例恶性淋巴瘤进行分析,现综述如下。 1 消化系统消化道通常是淋巴瘤最容易侵犯的主要器官,蔡则     

E-cad在中枢神经系统白血病患者骨髓中的表达及意义

目的 探讨急性白血病(AL)患者骨髓血单个核细胞表面上皮型钙黏蛋白(E-cad)的表达及其在中枢神经系统白血病(CNSL)的发生、发展、浸润、复发、预后和疗效判定中的临床意义.方法 应用流式细胞术(FACS)检测骨髓血单个核细胞表面E-cad的表达.结果 AL组骨髓血单个核细胞(BM-MNC)表面E-cad的表达(%)显著低于对照组(P<0.01),非CNSL组又显著高于CNSL组(P<0.01);AL组治疗后显著高于治疗前(P<0.01);非高白细胞血症组显著高于高白细胞血症组(P<0.01).结论 AL患者骨髓血单个核细胞表面E-cad的表达与CNSL发生密切相关,E-cad表达的动态变化是反映AL患者病情及治疗效果的重要指标,可作为AL髓外浸润尤其是CNSL的诊断、鉴别诊断、用药监督和筛选、判定复发、疗效和预后的监测指标之一.     

12例间变性淋巴瘤激酶阳性间变性大细胞淋巴瘤临床分析

目的:分析间变性淋巴瘤激酶(ALK)阳性间变性大细胞淋巴瘤(ALCL)的临床特征,探讨治疗效果、预后影响因素及临床治疗方案。方法:收集2014年12月—2021年12月在徐州医科大学附属医院初治的12例ALK⁺ALCL患者的临床资料,回顾性分析其临床特点、治疗效果及预后生存情况。结果:12例患者的中位发病年龄为28(14～45)岁,其中男11例。11例(91.67%)患者初诊时评估晚期(Ⅲ～Ⅳ期),7例(58.33%)患者合并B症状,5例(41.67%)患者LDH升高,4例(33.33%)患者以浅表淋巴结肿大为首发部位,7例(58.33%)患者伴有腹腔淋巴结肿大。6例(50.00%)患者伴有结外侵犯,3例(25%)患者≥2个结外部位侵犯。2例(16.67%)患者IPI评分为高中危/高危组(3～5分);7例(58.33%)患者aaIPI评分为高中危/高危组(3～5分)。Ki-67≥80%、结外侵犯≥2处、aaIPI 3～5分、一线化疗方案是影响初始化疗后达CR的不良因素。CRP升高、结外侵犯≥2处、IPI 3～5分、aaIPI 3～5分、Ki-67≥80%、一线化疗...     

环氧合酶-2在不同病理类型非霍奇金淋巴瘤组织中的表达及其临床意义

目的:探讨环氧合酶-2(COX-2)在不同病理类型非霍奇金淋巴瘤(NHL)组织中的表达及其与患者临床特征的关系。方法:采用免疫组织化学EnVision二步法检测96例NHL和20例恶性肿瘤患者切除组织中未累及之淋巴结中COX-2的表达,回顾性分析患者的分期、分组、结外侵犯等临床特征。结果:COX-2在NHL中的阳性表达率为39%(37/96),对照组为15%(3/20),差异有统计学意义(P<0.05)。不同病理类型之间COX-2表达差异有统计学意义(P<0.01),其中鼻型结外NK/T细胞淋巴瘤、黏膜相关淋巴组织结外边缘区淋巴瘤(MALT淋巴瘤)、血管免疫母细胞T细胞淋巴瘤组织中COX-2阳性率分别为83%(10/12)、71%(5/7)和57%(4/7)。有结外侵犯的患者COX-2阳性率显著高于无结外侵犯者(P<0.01),有无B组症状的NHL患者之间COX-2阳性率差异有统计学意义(P<0.05)。结论:NHL中COX-2表达上调,但不同病理类型之间COX-2表达差异较大,高表达COX-2的NHL患者易于出现结外侵犯及B组症状。     

类风湿关节炎并发淋巴瘤的临床特征

目的探讨类风湿关节炎(rheumatoid arthritis,RA)并发恶性淋巴瘤(malignant lymphoma,ML)患者的临床特点。方法回顾性分析2005年1月至2014年11月北京协和医院收治的RA并发ML患者的临床资料。结果 RA并发ML患者共11例,占同期RA住院病例的0.53%(11/2093),其中女性7例,男性4例;RA平均确诊年龄(48.18±12.66)岁(25~67岁);ML平均确诊年龄(65.55±8.07)岁(49~75岁);RA确诊到诊断ML病程平均(17.36±10.03)年(2~40年)。所有淋巴瘤病理类型为非霍奇金淋巴瘤;且淋巴结结外受累多见,共6例,占54.5%(6/11)。ML可以侵犯到全身组织和器官,其中胃肠道受累1例,骨髓受累1例,皮下组织受累2例,黏膜组织受累3例。11例RA合并ML的患者中10例炎性指标明显升高(C反应蛋白/红细胞沉降率)。结论 RA并发ML比普通人群风险高,当长病程RA患者出现不明原因发热、组织肿物、淋巴结肿大,需警惕RA并发ML的可能,当RA并发ML多数对化疗敏感。     

胃肠道恶性淋巴瘤

淋巴瘤的分期Ann Arbor分类法为对恶性淋巴瘤患者病变范围的分类。分类法如下:Ⅰ期:单个淋巴结部位受侵(Ⅰ)或只有单个淋巴结外器官或部位受侵(Ⅰ_E);Ⅱ期:在横膈的同一侧有二个或更多淋巴结部位受侵(Ⅱ)或局限的相邻淋巴结外的器官或组织受侵(Ⅱ_E);Ⅲ期:横膈的两侧多个淋巴结部位受侵(Ⅲ),可包括脾脏(Ⅲ_s)或局限的相邻淋巴结外器官或组织受侵(Ⅲ_E),或两者均累及(Ⅲ_(Es));Ⅳ期:一个     

老年人结外恶性淋巴瘤外周血免疫指标测定分析

目的检测老年人结外恶性淋巴瘤(PENL)患者外周血T淋巴细胞亚群比例和免疫球蛋白(Ig)水平的变化。方法76例恶性淋巴瘤患者分成2组原发性结外淋巴瘤(结外组)36例,原发性结性淋巴瘤(结性组)40例,另取非淋巴瘤(炎性组)20例作为对照组。分别应用流式细胞术(FCM)和免疫速率比浊法测定T淋巴细胞亚群比例免疫球蛋白(Ig)和Ig以及C3、C4含量。结果结外组CD3 、CD4 和CD8 明显降低(P<0.01),原发性结性恶性淋巴瘤(结性组)CD4 /CD8 比值和NK细胞较其他2组差异有显著性(P<0.01);结外组、结性组中CD3 、CD4 和NK细胞与IgA、IgG、C3有显著的相关性(P<0.01)。结论PENL患者免疫功能的改变,可以作为病情进展的免疫学指标。     

结直肠癌淋巴结的分期

目的:分析结直肠癌淋巴结转移状况与预后的关系,提出新的结直肠癌淋巴结分期方案.方法:122例病理资料完整的结直肠癌病例,比较不同删分期(AJCC/UICC)病例的5年生存率:将淋巴结转移数目≥10枚和顶端淋巴结转移拟定为N,期,比较AJCC/UICC的TNM分期中No、N1、N2与N3期病例的5年生存率;按Kaplan-Meier方法计算生存率,绘制生存曲线,并对生存率进行Log-rank检验.结果:随着TNM分期的上升,5年生存率逐渐下降(Ⅰ期为100%;Ⅱ期为81.82%;ⅢAB期为69-39%,ⅢC期为15%:Ⅳ期为0,P<0.01),随着N分期的上升,5年生存率也逐渐下降(N0Ⅰ期为100%、N0Ⅱ期为89.82%、N1期69.39%,N2期为15%,P<0.01).N3期病例5年生存率为0,与TNM的Ⅳ期预后相似.结论:建议将结直肠癌TNM中的N分期定为:无淋巴结转移为N0,1-3枚淋巴结转移为N1,4-9枚淋巴结转移为N2,≥10枚淋巴结转移和/或顶端淋巴结转移为N3.N3期患者的5年生存率为0,与M1期结果相似,可以定为亚临床转移.     

癌组织及外周血中CD44、PLCEl、甲基化Sept9基因及DNA错配修复蛋白表达水平与结直肠癌病理分期及预后的相关性分析

目的探讨癌组织及外周血中白细胞分化抗原分化簇第44号(CD44)、磷酯酶Cεl(PLCEl)、甲基化Sept9基因及DNA错配修复蛋白表达水平与结直肠癌病理分期及预后的相关性。方法将2013年3月至2015年5月在西宁市第二人民医院确诊为结直肠癌的56例患者设为观察组,将同期于我院体检的55名健康成年人设为对照组。比较两组甲基化Sept9基因、CD44、PLCEl及DNA错配修复蛋白表达情况,分析以上指标在结直肠癌患者中的临床分布特点并进行相关性检验,比较不同甲基化Sept9基因、CD44、PLCEl及DNA错配修复蛋白表达情况并分析其与结直肠癌患者的预后相关性。结果观察组甲基化Sept9基因及CD44表达阳性率、PLCEl表达阴性率、DNA错配修复蛋白表达缺失率高于对照组(P<0.05)。甲基化Sept9基因、PLCEl及DNA错配修复蛋白在不同肿瘤浸润深度、肿瘤大小、病理分期及有无淋巴结转移结直肠癌患者中的表达差异有统计学意义(P<0.05)。CD44在不同肿瘤浸润深度、病理分期及有无淋巴结转移结直肠癌患者中的表达差异有统计学意义(P<0.05)。PLCEl与结直肠癌的浸润深度、病理分期呈负相关(r=-0.367,P=0.045;r=-0.522,P=0.008);甲基化Sept9基因与浸润深度、病理分期、淋巴结转移呈正相关(r=0.715,P=0.026;r=0.471,P=0.032;r=0.453,P=0.010),CD44与浸润深度、病理分期、淋巴结转移呈正相关(r=0.349,P=0.007;r=0.591,P=0.022;r=0.452,P=0.027),DNA错配修复蛋白与病理分期﹑淋巴结转移呈负相关(r=-0.487,P=0.041;r=-0.551,P=0.030)。不同CD44、甲基化Sept9基因、PLCEl及DNA错配修复蛋白表达情况的结直肠癌患者3年生存率差异有统计学意义(P<0.05)。PLCEl、DNA错配修复蛋白与结直肠癌患者3年生存率呈正相关(r=0.574,P=0.041;r=0.478,P=0.037),甲基化Sept9基因与结直肠癌患者3年生存率呈负相关(r=-0.515,P=0.034)。结论CD44、PLCEl、甲基化Sept9基因及DNA错配修复蛋白均与结直肠癌的病理分期相关,其检测有助于了解疾病的恶性程度,评估患者预后。     

Cytogenetics with flow cytometry in lymph node/extranodal tissue biopsies is sensitive to assist the early diagnosis of suspected lymphomas

Few studies have examined the value of cytogenetic studies with flow cytometry (FC) in lymph node/extranodal tissue biopsies with suspected lymphoma. To evaluate this, G-banded karyotyping and/or fluorescence in situ hybridization (FISH) with FC immunophenotyping were performed on 185 lymph node or extranodal tissue biopsy specimens with suspected lymphoma. Complete cytogenetic analysis of lymph node/extranodal tissue was successful in 174 cases (94.1%) and 57.5% demonstrated chromosomal abnormalities. In 116 malignant lymphoma cases, 83.8% showed abnormalities. In 74 B cell lymphomas (B-NHL), abnormalities were more frequent in lymph node/extranodal tissues than in bone marrow by conventional cytogenetics (CC, 97.2 vs 26.1%), FISH (70.6 vs 17.6%), and FC (98.6 vs 28.4%). Three B-NHL diagnoses were confirmed by re-biopsy of lymph nodes due to the presence of abnormalities in the first biopsy, but no evidence of malignancy in pathological, FC, or IgH/TCR gene rearrangement analyses. In 29 T cell lymphomas (T-NHL), abnormalities were more frequent in lymph nodes than in bone marrow by CC (67.9 vs 21.4%) and FC (75.9 vs 27.6%) analyses. As expected, in 13 Hodgkin lymphoma cases, abnormalities were more frequent in lymph nodes than bone marrow by CC (41.7 vs 16.7%) and FC (30.8 vs 7.7%) analyses. In 56 reactive lymphoid hyperplasias (RLH), 7.1% had conventional clonal cytogenetic abnormalities. Two of these patients died of disease progression and two had their pathological diagnosis revised after the second review. These findings indicate that cytogenetic analysis combined with FC in lymph node/extranodal tissue biopsies can provide critical information in the auxiliary diagnosis of lymphoma.     

Extranodal T-cell lymphoma mimicking malignant histiocytosis

We report a case of extranodal T-cell lymphoma with fever, hepatosplenomegaly, pancytopenia, and diffuse sinusoidal infiltration of the spleen, liver, and bone marrow by the tumor cells, mimicking malignant histiocytosis. This is the second case of T-gamma (T-cell suppressor) lymphoma resembling the case reported by Kadin et al. [N Engl J Med 304:648, 1981]. The lack of lymph node involvement in this case supports the theory that this type of lymphoma arises in the spleen. This paper draws attention to the extranodal T-cell lymphoma groups that mimic malignant histiocytosis and the need of immunophenotyping for a correct diagnosis. The causes for the absence of T-cell receptor gene rearrangement in T-cell tumors are discussed.     

Reliability of lymphoma classification in bone marrow trephines

The aim of this study was to test and establish the accuracy and reliability of lymphoma classification in bone marrow trephines according to the new World Health Organization (WHO) classification by considering predominantly the morphology and immunophenotype. Therefore, we retrospectively compared lymphoma diagnoses, rendered exclusively on bone marrow trephines without knowledge of lymph node diagnosis in 124 patients, with the results of the reference centres that had reviewed lymph node (n = 90) or extranodal biopsies (n = 34). The overall concordance rate was higher than 85% and 91%, respectively, when patients with discordant malignancy grades were excluded. The concordance rate for low-grade B-cell lymphomas was 93% and for high-grade B-cell lymphomas 84%. The main reasons for discordant diagnoses were divergent immunophenotypes among low-grade B-cell lymphomas (6 out of 81, i.e. 7.4%) and discrepant malignancy grades within high-grade B-cell lymphomas (6 out of 31, i.e. 19.4%). No relationship between discordant diagnoses and chemotherapy given during the course of the disease with the site of biopsy (i.e. lymph nodes, extranodal sites) was noted. We conclude from our results that bone marrow trephines are a reliable tool, not only for establishing bone marrow infiltration, but also for the subtyping of lymphomas.     

Comparative histology of malignant lymphomas in lymph node and bone marrow

Lymph node and bone marrow biopsies of 226 patients with malignant lymphomas were available for evaluation and comparison. 120 of the 226 lymphoma patients had classifiable infiltration in both lymph node and bone marrow and these were used for comparison. Congruence in the histologic subtypes in lymph node and bone marrow was found in 91 patients (76%). The majority of the 29 cases with divergent histologies showed ML of low grade malignancy in the bone marrow even with long time intervals between the two biopsies. The most notable in this group were seven cases who had ML centroblastic/centrocytic in the lymph node biopsy and ML immunocytic in the bone marrow, although none had a serum M-component. 65 of the 106 patients excluded from comparison had involvement in only one organ, the others had unclassifiable or equivocal histologies in either lymph node or bone marrow or in both. The findings are discussed with respect to the histologic behaviour of the lymphomas. The results show that comparison between lymph node and bone marrow findings in patients with ML is feasible and clinically relevant.     

Impact of Microscopic Extranodal Tumor Deposits on the Outcome of Patients With Rectal Cancer

PURPOSE: Microscopic mesorectal soft tissue extranodal deposits discontinuous with the primary tumor are identified in many rectal adenocarcinomas. Current guidelines consider them to be involved lymph nodes. We studied the impact of these deposits on the outcome of patients with rectal cancer. METHODS: This was a retrospective study, in which histology slides were reviewed from 55 patients whose resection specimens for rectal cancer were staged as Dukes C or Dukes B with extranodal deposits. Twenty-nine patients had extranodal deposits (19 males), and 26 control patients had lymph node involvement only (14 males). Patient outcome was analyzed in terms of local and systemic control and survival. RESULTS: Distant metastases were diagnosed earlier in patients with extranodal deposits (mean, 14 months) compared with controls (mean, 37 months; P = 0.001). On follow-up, 31.03 percent (9/29) from the extranodal deposit group developed liver metastases compared with 11.5 percent (3/26) of the control group (P = 0.08). Local recurrence was seen in 17.2 percent of patients from the extranodal deposit group and 3.8 percent of the control group (P = not significant). Cancer-related mortality was higher in the extranodal deposit group (16 vs. 7 patients; P = 0.09). The three-year actuarial survival was 48.27 percent in patients with extranodal deposits and 65.38 percent in those without. A significant association was noted between the number of extranodal deposits and intramural vascular invasion (P = 0.017), extramural vascular invasion (P = 0.039), perineural invasion (P = 0.039), and lymph node involvement (P = 0.008). CONCLUSION: These data suggest that extranodal deposit is a distinct form of metastatic disease in patients with rectal cancer. The association with vascular invasion and earlier development of metastases probably infers that a significant proportion of extranodal deposits may represent blood-borne spread. These tumor foci should be considered as indicators of poor prognosis.     

Analysis of clinical characteristics and prognosis of patients with peripheral T-cell lymphoma

Background:This study aimed to explore the clinical characteristics, therapeutic efficacy and prognostic factors of peripheral T-cell lymphoma (PTCL).Methods:The clinical data of 119 PTCL patients who were admitted to the Xinjiang Medical University Affiliated Tumor Hospital from January 2010 to December 2017 were retrospectively analyzed, including the clinical characteristics, therapeutic efficacy, prognosis-related factors and treatments. Among the patients, 98 patients received antharcyclines-based therapeutic protocols, including Cyclophosphamide, Pirarubicin, Vincristine, Prednisone (CHOP) protocol and Cyclophosphamide, Pirarubicin, Vincristine, Prednisone, Etoposide (CHOPE) protocol, with median follow-up time of 32.5 months (2–166 months). The patients’ clinical characteristics were analyzed, and COX ratio risk regression model was adopted to analyze the prognostic factors related with the survival rate of PTCL patients.Results:The 5-year overall survival (OS) rate was 46.4% and progression-free survival (PFS) rate was 42.7% in the 98 patients, and there were insignificant differences between patients with CHOP protocol and those with CHOPE protocol in the 5-year OS and PFS rates (OS: P = 0.197, PFS: P = 0.663). The univariate analysis results showed that different pathological types, Ann Arbor stage, Eastern Cooperative Oncology Group (ECOG) score ≥ 2, the number of extranodal lymphomas involved, Lactic dehydrogenase (LDH) level, presence/absence of bone marrow involved, international prognostic index (IPI) score, β₂ microglobulin (β₂-MG) level and hemoglobin (Hb) level were poor prognosis factors influencing patients’ OS and PFS rates (P all < .05). Multivariate analysis demonstrated that different pathological types, Ann Arbor stage, presence/absence of bone marrow involved and Hb level were independent prognostic indicators influencing patients’ OS and PFS rates (P all < .05).Conclusion:PTCL is poor in therapeutic efficacy and prognosis, and different pathological types, Ann Arbor stage, presence/absence of bone marrow involved and Hb level are related with the prognosis of PTCL patients. Anemia occurring before the treatment is an important predictive indicator influencing the prognosis of PTCL patients and patients who experience anemia will be poor in prognosis.     

Investigation of the prognosis of patients with papillary thyroid carcinoma by tumor size

In papillary thyroid carcinoma (PTC), extrathyroid extension (Ex) and clinical lymph node metastasis (N) significantly affect the prognosis. We investigated the prognosis of patients with PTC 1 cm or less (1,220 patients), 1.1-2 cm (2,101 patients), 2.1-3 cm (1,249 patients), 3.1-4 cm (645 patients), and larger than 4 cm (563 patients). We classified N factor into three categories: N0, no clinical node metastasis: N1, clinical node metastasis smaller than 3 cm and without extranodal tumor extension requiring at least partial excision of adjacent organs for node dissection: and N2, clinical node metastasis 3 cm or larger or showing extranodal tumor extension. N2 markedly affected lymph node and distant recurrence-free survivals and cause-specific survival, regardless of the tumor size. N1 also adversely affected lymph node and distant recurrence-free survival but not cause-specific survival. Ex did not affect patients' prognosis with PTC 1 cm or less. It became a prognostic factor with PTC larger than 1 cm, and worsened lymph node and distant recurrence-free survival not only for N0 but also for N1 PTC larger than 3 cm and larger than 2 cm, respectively. However, its influence is limited for N2 PTC patients. Furthermore, Ex worsened the CSS with PTC larger than 2 cm in combination with N2. We have to note that the prognostic significance for lymph node and distant recurrence-free and cause-specific survival of Ex and N varies according to the tumor size in order to accurately predict the clinical outcomes and establish therapeutic strategies for PTC patients.     

Head and neck extranodal lymphoma in a single institute: a 17-year retrospective analysis

The study's purposes are to identify patient characteristics, treatment response and survival rate, and to describe the important prognostic factors for our patients with extranodal head and neck lymphoma. Furthermore, no study has systemically discussed the overall figure of this disease in Taiwan and we analyzed our data on this topic. A retrospective review was performed for 86 patients with extranodal head and neck lymphoma, diagnosed in Kaohsiung Medical University Hospital, between 1990 and 2007. We evaluated the medical records and analyzed the possible factors affecting treatment outcomes, survival rate, and free-from-disease (FFD) survival rate. Forty-nine male and 37 female patients were included with a male:female ratio of 1.32:1. The most frequent histologic type was diffuse large B cell lymphoma, accounting for 41.9% of the total. The most common primary site involved with extranodal head and neck non-Hodgkin's lymphoma was a tonsil with 27 cases (31.4%). Stage, international prognostic index (IPI) score, B symptoms, lactate dehydrogenase (LDH) level, and lymph node status significantly affected treatment response. The overall 5- and 10-year survival rates were 68.0% and 57.8%, respectively. The FFD survival rate was 53.6% and 49.3% at 5 and 10 years, respectively. Factors including stage, lymph node status, LDH level, and IPI score produced significant differences in both overall survival and FFD survival. Our analyzed information is similar to other previously presented studies. Stage, IPI score, B symptoms, LDH level, and neck nodal status can be used to evaluate the treatment outcomes. Neck nodal status and stage are the two significant prognostic factors for overall survival.     

A unique pattern of extranodal involvement in Korean adults with sporadic Burkitt lymphoma: a single center experience

Extranodal involvement is common in patients with Burkitt lymphoma (BL). We evaluated the pattern of extranodal involvement and its impact on clinical outcomes in a single center cohort of adult Korean patients with sporadic BL. We retrospectively identified 64 patients with BL in the registry of non-Hodgkin lymphoma of the Asan Medical Center between 1996 and 2009. We assessed their clinical features and distribution of extranodal sites and analyzed clinical outcomes, including complete response rate after chemotherapy, overall survival, and progression-free survival, relative to baseline characteristics and involved extranodal sites. Extranodal involvement was found in 57 patients (89?%), with 34 (53.1?%) having two or more extranodal sites. The stomach (26.6?%) was the most common site, followed by the small and large intestines (25?%), bone marrow (23.4?%), genitourinary tract (21.9?%), and bones (18.8?%). Two patients (3.1?%) showed central nervous system (CNS) involvement. Complete response rates to chemotherapy were not related to sites of extranodal involvement. Two-year overall survival rates were lower in patients with bone marrow (33.3 vs. 74.6?%, p?=?0.010) and CNS (0.0 vs. 66.6?%, p?=?0.048) involvement than in patients with involvement at other extranodal sites. The stomach, genitourinary tract, and bones were the most commonly involved extranodal sites in Korean BL patients, but site had no prognostic significance.     

小鼠口腔癌不同时期淋巴结和骨髓的VEGF表达情况及其微环境对淋巴道转移的影响

目的 探讨小鼠口腔癌不同时期淋巴结和骨髓的血管内皮生长因子(VEGF)表达情况,及其微环境对口腔癌淋巴道转移的影响.方法 选入40只6周龄雄性健康Balb/c小鼠,将其随机分为A、B、C、D、E组,每组8只.采用4-硝基喹啉-1-氧化物(4-NQO)饮水法构建小鼠口腔癌淋巴道转移模型.其中A组为正常小鼠;B组小鼠舌部黏...